189 related articles for article (PubMed ID: 18421048)
1. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors.
Siu LL; Pili R; Duran I; Messersmith WA; Chen EX; Sullivan R; MacLean M; King S; Brown S; Reid GK; Li Z; Kalita AM; Laille EJ; Besterman JM; Martell RE; Carducci MA
J Clin Oncol; 2008 Apr; 26(12):1940-7. PubMed ID: 18421048
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay.
Bonfils C; Kalita A; Dubay M; Siu LL; Carducci MA; Reid G; Martell RE; Besterman JM; Li Z
Clin Cancer Res; 2008 Jun; 14(11):3441-9. PubMed ID: 18519775
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.
Garcia-Manero G; Assouline S; Cortes J; Estrov Z; Kantarjian H; Yang H; Newsome WM; Miller WH; Rousseau C; Kalita A; Bonfils C; Dubay M; Patterson TA; Li Z; Besterman JM; Reid G; Laille E; Martell RE; Minden M
Blood; 2008 Aug; 112(4):981-9. PubMed ID: 18495956
[
